EUROPEAN PROGRAM

FOR PREVENTION 2025

MULTI-GAP (MULTI Goal Attainment Problem) Study

Description

In the MULTI-GAP (MULTI Goal Attainment Problem) study, data from 2332 patients with cardiovascular events were processed. Serum total cholesterol, LDL, HDL, triglyceride levels were assessed, and it was found that 15% of the patients studied did not receive lipid-lowering treatment, 44% of patients treated by specialists achieved the LDL target, 61% of patients at high risk achieved the HDL target, while 43% of patients achieved the triglyceride target. The results suggested more effective lipid-lowering treatment, higher-dose statin use, and combination drug therapy. (I Reiber, Gy Paragh, L Márk, Gy Pados: Orvosi Hetilap 2011;152, 21: 822-827.) In 2011 and 2012, MULTI-GAP examined patient medication compliance with physician prescribing habits. It found that medication cooperation and goal achievement showed a linear relationship. Based on an analysis of data from around 450 000 patients, statin persistence showed that 54% of patients stopped therapy in the first month, 38% remained on statin therapy after the second month, only 27% after six months and 20% after one year. Among patients with acute coronary syndrome, 76% of patients were still on statins at 1 month, 62% at 6 months and 50% at 1 year. (L Márk, I Reiber, Gy Paragh, I Karádi, Gy Pados, Z Kiss: Metabolizmus XI., 3. 2013:177-181) The MULTI-GAP 2013 study investigated the adherence and persistence of statin therapy in patients with atherosclerotic disease. Data from 1519 patients were processed for the study. The study showed that the true persistence of patients assessed by their treating physicians as having 100% persistence was 74%, 25% lower than the true persistence. And the adherence rate was 36%. (G Simonyi Orvosi Hetilap 155(17) 2014:669-675.) We investigated the relationship between daily practice and recommendation in 12 997 patients with acute coronary syndrome undergoing revascularisation. Our study showed that lipid-lowering treatment was reduced during follow-up. Higher-intensity lipid-lowering treatment had higher persistence and adherence and better mortality. Lower statin dose use was observed more frequently for several diseases. (G Gy Nagy, L Mark, A Gerencser, I Reiber, N Kiss, Gy Rokszin, I Fabian, Z Csanádi, I Karádi, D Aradi, L Bajnok, Gy Paragh: Journal Clinical Medicine 2024;13, 6562.)

Program launch date

N/A

Responsible entity

N/A

Available results and quality metrics

Not available.

Limitations / comments

N/A